Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report

Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report

Abstract Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient...

Full description

Bibliographic Details
Main Authors: Yuki Awanami, Makoto Fukuda, Yasunori Nonaka, Tsuyoshi Takashima, Keiichiro Matsumoto, Masatora Yamasaki, Motoaki Miyazono, Yuji Ikeda
Format: Article
Language:English
Published: BMC 2017-07-01
Series:BMC Nephrology
Subjects:
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Evolocumab
Nephrotic syndrome
Case report
Online Access:http://link.springer.com/article/10.1186/s12882-017-0644-0

Internet

http://link.springer.com/article/10.1186/s12882-017-0644-0

Similar Items